Spero Therapeutics raises $30M


What does Spero Therapeutics do?

Spero Therapeutics, is developing first in class therapeutics for treating gram negative infections. It is leverages a top tier chemistry and microbiology team, which is an efficient virtual approach to drug developing, focusing on high potential and novel mechanisms for fulfilling the unmet needs for early stage therapeutics which target bacterial infections. The company’s lead program addresses a novel target driving persistence and virulence of Pseudomonas Aeruginosa infections and other gram negative pathogens.

How much Spero Therapeutics was funded?

Spero Therapeutics raised   $30M in Series A funding on June 8, 2015 from Lunderbeckfond Ventures, Merck Research Ventures, Partners Innovation Fund, GlaxoSmithKline, SR One, Atlas Venture, Kraft Group, New England Patriots and other angel investors.

Previous funding

Undisclosed amount in Seed funding on January 1, 2010 from Atlas Partner

$3M in Series A funding on April 9, 2014 from Atlas Partner

What is next for Spero Therapeutics?

Spero Therapeutics has expanded its pipeline of novel anti-infectives by adding a Potentiator program targeting Gram negative infections. The company plans to use the latest funds raised for advancing the Potentiator franchise into clinical development by 2015, progress its anti-virulence program for partnering with Roche via submission of IND- Investigational New Drug application, and to develop additional programs in its pipeline for focusing on the unfulfilled needs in bacterial infections.

More about Spero Therapeutics

Spero Therapeutics was founded in 2013 by Laurence Rahme. It has its headquarters in Cambridge, MA. The vision of this biopharmaceutical company is to find, develop and advance groundbreaking therapeutics for meeting the unmet critical patient’s needs in infectious diseases. Its pipeline of anti-infective agents is one of the most unique in the industry focused on the bacterial infections caused by Gram negative bacteria. The company feels it is a part of something groundbreaking and innovative and this is what fuels its approach.